达托霉素
医学
不利影响
回顾性队列研究
队列
内科学
儿科
外科
万古霉素
金黄色葡萄球菌
遗传学
生物
细菌
作者
Bryan Vonasek,Allison M. Samuel,Sheryl L. Henderson,Jill R. Strayer,Monica C Bogenschutz
标识
DOI:10.1177/00099228241242186
摘要
Daptomycin is a common treatment for serious infections caused by gram-positive bacteria in adult patients; however, data regarding its safety and efficacy in the pediatric population are limited. This was a retrospective chart review of adverse reactions and treatment outcomes associated with daptomycin use in children <13 years old who received at least 1 dose of daptomycin. At least 1 dose of daptomycin was received by 147 patients. Seventy-two patients received daptomycin for 5 or more days. New-onset loose stools on daptomycin initiation were reported for 14 (9.5%) patients, elevations in creatine kinase in 3 (2%) patients, and elevated aspartate transaminase and alanine transaminase in 13 (8.8%) and 9 (6.1%) patients, respectively. Two patients (1.4%) had daptomycin discontinued due to specific concerns for adverse drug reactions. Daptomycin was found to be safe and effective in this pediatric cohort that included young children and infants with a variety of types and severities of infections.
科研通智能强力驱动
Strongly Powered by AbleSci AI